Kazakhstan Medical Device Registry Teardown: NDDA Database Analysis
A quantitative teardown of Kazakhstan's NDDA State Register: 32,117 total registrations (14,048 active), EAEU risk class split, and clinical areas.
Kazakhstan Medical Device Registry Teardown
For medical device and IVD manufacturers targeting Central Asia and the Eurasian Economic Union (EAEU), Kazakhstan represents the largest commercial opportunity and the primary regulatory gatekeeper in the region. The National Center for Expertise of Medicines and Medical Devices (NDDA or NCEMMD - Национальное бюро экспертизы лекарственных средств и медицинских изделий), under the Ministry of Health of the Republic of Kazakhstan, maintains the national State Register (Государственный реестр). As the country navigates a prolonged transition toward unified EAEU regulations, the registry is a critical read on market size, EAEU-aligned risk class distribution, and lifecycle activity.
A quantitative teardown of the NDDA State Register (snapshot compiled on June 21, 2026, with active status verified as of June 22, 2026) reveals several key structural metrics:
- Total Registry Volume: 32,117 total medical device registrations.
- Active Registrations: 14,048 (43.7%) are currently active. This indicates that over half (56.3%) of all registrations ever issued in Kazakhstan are expired or inactive, reflecting the critical importance of post-market lifecycle management.
- EAEU-Aligned Risk Class Distribution (Full Register): The register is dominated by medium-risk devices. Class 2a (medium risk) leads with 11,401 registrations (35.5%), followed by Class 1 (low risk) with 9,202 (28.6%), Class 2b (elevated risk) with 6,357 (19.8%), and Class 3 (high risk) with 3,565 (11.1%). A small portion (1,592 records / 5.0%) carries no recorded risk class.
- Active Product Characteristics: Within the 14,048 active registrations, 1,806 (12.9%) carry an In Vitro Diagnostics (IVD) flag (
invitroSign), 3,378 (24.0%) are flagged as sterile (sterilitySign), and 369 (2.6%) carry a measurement-device flag (measurementSign). - Registration Year Trends: Throughput peaked following the full implementation of EAEU regulatory deadlines. 2022 saw the largest cohort with 4,212 registrations, followed by 2023 with 2,378, 2025 with 2,100, 2024 with 1,879, and 773 registrations already recorded in the first half of 2026.
- Clinical Area Footprint (Active Subset): Dentistry/stomatology leads with 942 registrations, followed by ophthalmology at 537, surgery at 478, and clinical laboratory diagnostics at 382.
This teardown sizes the Kazakh medical device database, breaks down EAEU risk classes, analyzes active versus expired lifecycles, and maps the leading clinical segments. Regionally, this analysis pairs with our EAEU medical device registration guide (Russia, Kazakhstan, Belarus, Armenia, Kyrgyzstan) and our Uzbekistan medical device registry analysis.
Methodology Note: This analysis is based on the June 21, 2026 compiled snapshot of the NDDA State Register of Medicines and Medical Devices maintained by the Ministry of Health of Kazakhstan, filtering specifically for medical device records (
regTypeId=2). Active status is calculated as of June 22, 2026, using the rule: registrations with an unlimited validity flag (unlimitedSign=true), a null expiry date, or an expiry date on or after June 22, 2026. Proportional calculations exclude the 1,592 records with missing risk classes from their respective denominators where noted.
Kazakhstan's Regulatory Framework: The Dual Pathway (National vs. EAEU)
Kazakhstan's medical device market is regulated under a unique dual-pathway framework. Manufacturers can choose between the national Kazakh registration route or the unified EAEU supranational route:
- National Registration Pathway (Order KR DSM-16): Regulated by the Ministry of Health of Kazakhstan under Order KR DSM-16 of February 9, 2021. This pathway grants a national registration certificate valid only in Kazakhstan.
- The EAEU Pathway: Regulated by the Eurasian Economic Union (EEC). This pathway allows a single technical file and audit to be accepted across all five EAEU member states (Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan) through a single application process, designating a "Reference State" and "Recognition States."
- The Dec 31, 2027 EAEU Transition Deadline: The national registration pathway for new medical devices was originally scheduled to close, but EAEU Council agreements have repeatedly extended the transition. The current deadline for filing new applications under the national pathway is December 31, 2027. After this date, all new medical device registrations must go through the EAEU unified pathway.
- Unlimited Validity of National Certificates: A key regulatory advantage is that Kazakh national registration certificates issued before the December 31, 2027 deadline carry unlimited validity (unless they are modified or require safety-related review). This makes the current window highly strategic: filing nationally before the deadline locks in permanent, low-maintenance access to the Kazakh market, avoiding the longer, more expensive EAEU recognition procedures.
- Language and Translation Requirements: All technical submissions, packaging, labeling, and Instructions for Use (IFU/User Manual) must be provided in both Russian and Kazakh. Finding qualified technical translators is a key requirement for market entry.
How large is the Kazakhstan NDDA medical device register, and how much of it is currently active?
The NDDA State Register contains 32,117 total registrations. However, only 14,048 (43.7%) are active, while 18,069 (56.3%) have expired or are inactive.
This large volume of expired registrations is a unique feature of the Kazakh database. It occurs because early national registrations carried five-year limits, and many manufacturers elected not to renew their registrations due to product obsolescence, corporate mergers, or shifts to EAEU-wide files.
For manufacturers entering the market, this active-vs-expired split highlights that the registry's total volume (32,117) is an inflated measure of active competitors. Competitor benchmarking should focus on the 14,048 active registrations, which represent the products currently being imported and sold.
How are registrations distributed across the EAEU Class 1/2a/2b/3 risk classes?
Kazakhstan uses the standard EAEU four-tier risk classification, which aligns with international GHTF standards. Across the 30,525 records that carry valid risk-class data in the registry, the distribution is as follows:
| Risk Class (EAEU standard) | Number of Registrations (Total) | Percentage Share (Total) | Number of Active Registrations | Percentage Share (Active) |
|---|---|---|---|---|
| Class 1 (Low Risk) | 9,202 | 30.1% | 3,370 | 24.0% |
| Class 2a (Medium Risk) | 11,401 | 37.4% | 5,359 | 38.2% |
| Class 2b (Elevated Risk) | 6,357 | 20.8% | 3,257 | 23.2% |
| Class 3 (High Risk) | 3,565 | 11.7% | 2,062 | 14.7% |
| Total | 30,525 | 100.0% | 14,048 | 100.0% |
| No Data / Missing Class | 1,592 | - | 0 | - |
Note: Proportional shares are calculated using the 30,525 records carrying valid class data as the denominator for total registrations, and 14,048 for active registrations.
Several key insights emerge from this risk distribution:
- Medium-Risk Dominance: Class 2a represents the largest segment, accounting for 38.2% of active registrations. This class includes common diagnostic equipment, dental materials, and standard monitoring devices.
- High-Risk Implant Footprint: Class 3 (high-risk) implants, cardiovascular stents, and active implantable devices represent 14.7% of active registrations (2,062 records). This is a substantial high-risk footprint compared to smaller Balkan registries, indicating that Kazakhstan's public healthcare system actively funds complex surgical procedures.
- Low-Risk Active Base: Class 1 devices represent 24.0% of active registrations. This lower share compared to total registrations (30.1%) indicates that low-risk consumables are more likely to expire and not be renewed, as distributors frequently switch brands or sources.
What share of active registrations are IVDs, and which clinical areas dominate?
Within the 14,048 active registrations, we can analyze the product mix through specific diagnostic and clinical fields:
Active IVD Share
The registry flags in-vitro diagnostics via the invitroSign field. 1,806 active registrations (12.9%) are flagged as IVDs, representing a significant market for reagents, analyzers, and control materials.
Sterile and Measuring Devices
- Sterile Devices (
sterilitySign): 3,378 records (24.0%) are flagged as sterile, representing surgical sutures, catheters, syringes, and implantable systems that require sterilization validation. - Measuring Devices (
measurementSign): 369 active records (2.6%) carry the measurement flag. While a minority of registrations, these devices — patient monitors, thermometers, and diagnostic analyzers — are precisely the ones that trigger Kazakhstan's separate metrological type-approval regime (detailed below), so any measuring instrument must budget for that additional certification step.
Clinical Area Analysis
The NDDA registry records the primary clinical application (useArea field) for active registrations. The leading clinical areas are:
| Clinical Area (English Translation) | Original Russian Label | Number of Active Registrations |
|---|---|---|
| Dentistry / Stomatology | Стоматология | 942 |
| Ophthalmology | Офтальмология | 537 |
| Surgery | Хирургия | 478 |
| Clinical Laboratory Diagnostics | Клиническая лабораторная диагностика | 382 |
| Laboratory Diagnostics | Лабораторная диагностика | 232 |
| Vascular Surgery | Сосудистая хирургия | 157 |
Dentistry leads the active register with 942 registrations, indicating that the private dental sector in Kazakhstan, similar to Moldova, is a highly active buyer of registered orthodontic and dental consumables. Ophthalmology (537) and general surgery (478) follow, representing the core specialties for surgical equipment and device imports.
The NDDA Submission and Examination Timeline
Navigating the NDDA process requires a realistic understanding of the examination phases. Once an application is submitted via the electronic system, the NDDA conducts evaluation across four consecutive stages:
- Initial Assessment (Первичная экспертиза): NDDA specialists review the completeness of the administrative and technical file. This stage typically takes 30 calendar days. Any missing documents trigger a request for additional information (AI), which the applicant must address within 30 days.
- Specialized Review (Специализированная экспертиза): The clinical and safety files are evaluated by clinical experts. This stage includes evaluating biological safety testing and QMS files, taking between 60 to 90 days.
- Laboratory Testing (Лабораторные испытания): Samples are tested locally in accredited laboratories. The testing program is defined during the specialized review and can take 30 to 60 days depending on the device complexity.
- Final Recommendation & Decision: The NDDA Scientific Council reviews the evaluation reports and issues a recommendation to the Ministry of Health. This final step takes 15 to 30 days.
- Overall Timeline: A standard Class IIa or IIb registration takes between 8 to 12 months from initial submission to certificate issuance. High-risk Class III devices requiring local clinical reviews can exceed 14 months.
Detailed Local Testing Requirements in Kazakhstan
Unlike European pathways that rely entirely on document reviews, Kazakhstan's NDDA requires local testing and QMS evaluation as part of the registration process:
- Technical Testing (Технические испытания): Conducted at accredited laboratories in Kazakhstan. Testing verifies that the device meets technical specifications, mechanical safety, and electrical standards.
- Biological Safety Testing (Токсикологические испытания): Required for all patient-contacting devices. Testing evaluates biocompatibility, cytotoxicity, and systemic toxicity. NDDA frequently requires local testing even if the manufacturer holds an international ISO 10993 report.
- Clinical Evaluation (Клинические испытания): For Class IIa, IIb, and III devices, NDDA requires a clinical evaluation. This can be conducted through a document review of clinical trials conducted in the EU or US. However, for Class III implants or novel technologies, NDDA may require local clinical trials at designated medical centers in Kazakhstan.
- Metrological Certification: Devices with a measurement function (e.g., blood pressure monitors, patient monitors, diagnostic analyzers) must undergo metrological testing to be registered in the State System of Metrology.
The Metrology Register and Measurement Verification (GOST/GSI)
Devices with an active measurement function (measurementSign=true in the NDDA registry) face an additional regulatory layer. Under the Kazakhstan Law on Ensuring the Uniformity of Measurements, such devices must be registered in the State System of Scientific and Industrial Metrology (GSI):
- Type Approval (Утверждение типа средств измерений): The Committee for Technical Regulation and Metrology (Gosstandart) must issue a Type Approval Certificate. This requires shipping samples for metrological validation to verify measuring accuracy.
- Verification (Поверка): Every imported unit must undergo initial calibration/verification before clinical use, followed by periodic annual calibrations.
- Coordination: Metrological registration should run in parallel with the NDDA medical registration. Failure to secure metrological approval will block commercial sales, even if the NDDA has issued a valid registration certificate.
EAEU Reference State Selection: Why Choose Kazakhstan?
Under the unified EAEU pathway, manufacturers must select one EAEU member state as the Reference State to perform the primary technical review, QMS audit, and clinical evaluation. Choosing Kazakhstan as the Reference State is increasingly popular among B2B regulatory teams for several reasons:
- Lower Government Fees: The registration and examination fees charged by the NDDA are significantly lower than those charged by Russia's Roszdravnadzor. For a Class IIb or III device, selecting Kazakhstan as the Reference State can reduce initial registration fees by up to 40%.
- More Collaborative Review: The NDDA has established a reputation for a more interactive and collaborative evaluation process. Unlike the rigid deficiency letters typical of Roszdravnadzor, NDDA examiners frequently allow online clarifications and technical consultations to resolve minor dossier discrepancies.
- Audit Team Availability: Under EAEU QMS rules (EEC Decision No. 106), onsite manufacturing inspections are mandatory for Class IIa, IIb, and III devices. The NDDA audit teams are generally more available and have shorter scheduling lead times than their Russian counterparts, reducing overall registration timelines.
- Access to Recognition States: Once Kazakhstan issues the EAEU registration certificate, the manufacturer can apply for recognition in Russia, Belarus, Armenia, and Kyrgyzstan via a simplified document review, avoiding repeat audits.
QMS Audits under EAEU Decision No. 106
For manufacturers outside the EAEU trade zone, compliance with Eurasian Economic Commission (EEC) Decision No. 106 is a mandatory gatekeeper. This resolution defines the requirements for EAEU Good Manufacturing Practice (GMP) inspections:
- Onsite Inspections: Inspections are mandatory for Class IIa (sterile), IIb, and III devices, covering the manufacturing facilities, sterile assembly zones, packaging lines, and QC laboratories.
- Key Audit Focus Areas: Inspectors focus heavily on design controls, raw material traceability, environmental monitoring in cleanrooms, validation of sterilization processes, software validation, and post-market vigilance systems.
- Audit Frequency: Once granted, the EAEU GMP certificate is valid for three years, and periodic surveillance audits are conducted to maintain registry status.
Centralized Public Procurement via SK-Pharmacy
For medical devices, the single largest buyer in Kazakhstan is the government. Public sector procurement is consolidated under SK-Pharmacy (СК-Фармация), the designated Single Distributor for the country's public healthcare system:
- Centralized Tenders: SK-Pharmacy manages procurement for all public hospitals and clinics, purchasing medicines and medical consumables through annual centralized tenders.
- Bidder Requirements: To bid in an SK-Pharmacy tender, the local importer/distributor must present a valid NDDA registration certificate.
- Long-Term Contracts: SK-Pharmacy offers long-term (up to 10 years) supply contracts for companies that establish local medical manufacturing or assembly in Kazakhstan. This policy makes localized packaging or assembly a highly valuable strategy for long-term market capture.
EAEU Transition: How to Manage Local Authorized Representatives
Foreign manufacturers must appoint a local Authorized Representative based in Kazakhstan to act as the registrant. Similar to other regional registers, representative management is high-stakes:
- The Registrar Lock-In: The local representative holds the registration certificate in the NDDA database. If the manufacturer decides to change their local sales distributor, the current representative must sign a letter of consent to transfer the registration. If they refuse, the manufacturer must file a new registration from scratch.
- Transition to EAEU Representative: When transitioning to the unified EAEU pathway, the manufacturer must appoint a "Representative of the Manufacturer" in the Reference State. Choosing a reliable, independent partner in Almaty or Astana who can handle both Kazakhstan and EAEU-wide filings is critical.
Comparative Analysis: Kazakhstan vs. Central Asian and EAEU Regional Peers
To assist regulatory teams in regional sequencing, the table below compares Kazakhstan's NDDA register with its peers in Russia (EAEU) and Uzbekistan (independent national):
| Metric | Kazakhstan (NDDA) | Russia (Roszdravnadzor) | Uzbekistan (State Center) |
|---|---|---|---|
| Total Volume | 32,117 | ~110,000 | ~12,000 |
| Active Volume | 14,048 | ~75,000 | ~7,500 |
| EAEU Status | EAEU Member State | EAEU Member State | Non-EAEU / National |
| Transition Deadline | Dec 31, 2027 | Dec 31, 2027 | N/A (National pathway remains) |
| Certificate Validity | Unlimited (National) | Unlimited (National) | 5 Years |
| Local Testing | Technical, Tox, Metrology | Technical, Tox, Clinical | Technical, Tox, Clinical |
| Language | Russian & Kazakh | Russian | Russian & Uzbek |
| QMS Audits | Required for Class II/III | Required for Class II/III | Required for Class II/III |
This regional matrix highlights key differences:
- Scale: Kazakhstan represents the second-largest registry in the EAEU cluster (after Russia) and is nearly three times the size of Uzbekistan's register.
- Regulatory Strategy: Kazakhstan and Russia share the Dec 31, 2027 EAEU transition deadline and offer unlimited validity for national certificates. Uzbekistan remains outside the EAEU, maintaining its own national five-year registration system.
- Language Barriers: Kazakhstan is the only market requiring dual-language labeling (Russian and Kazakh), while Russia requires Russian, and Uzbekistan requires Russian and Uzbek.
Strategic Market-Entry Playbook for Kazakhstan
For regulatory affairs managers planning entry into Kazakhstan, we recommend the following structured approach:
Step 1: Leverage the National Pathway Window
Because national registration certificates carry unlimited validity, manufacturers should file applications under the national Kazakh pathway before the December 31, 2027 transition deadline. This locks in permanent access without requiring EAEU recognition.
Step 2: Prepare Dual-Language Materials
Prepare Russian and Kazakh translations for all labeling, user manuals, and packaging early. NDDA strictly audits translation quality, and discrepancies between Russian and Kazakh texts are a common cause of delay.
Step 3: Plan for Local Testing Timelines
Factor in the time required to ship samples and conduct local technical, biological, and metrological testing in Almaty or Astana. Budget 6 to 9 months for testing and registration of Class II and III devices.
Step 4: Verify Metrological Status
Determine if your device is classified as a measuring instrument. If yes, coordinate with a local metrological body to secure inclusion in the State Register of Measuring Instruments of the Republic of Kazakhstan alongside the NDDA registration.
Step 5: Establish a Compliant QMS
Ensure your manufacturing facility holds a valid ISO 13485 certificate. For Class IIb and III devices, prepare for potential inspections of your manufacturing facility by NDDA inspectors.
Frequently Asked Questions
Which regulator maintains the State Register of Medical Devices in Kazakhstan?
The National Center for Expertise of Medicines and Medical Devices (NDDA), under the Ministry of Health of the Republic of Kazakhstan, maintains the State Register.
Will Kazakhstan national medical device registrations remain valid after the EAEU transition deadline?
Yes. National registration certificates issued before the EAEU transition deadline (currently December 31, 2027) carry unlimited validity and remain valid unless modified or suspended for safety reasons.
What is the EAEU transition deadline for medical devices in Kazakhstan?
The transition deadline is December 31, 2027. After this date, all new medical device registrations in Kazakhstan must go through the unified EAEU registration pathway.
What languages are required for medical device labeling in Kazakhstan?
All labeling, packaging, and Instructions for Use (IFU) must be provided in both Russian and Kazakh.
How many active registrations are listed in the NDDA State Register?
As of June 22, 2026, there are 14,048 active registrations out of 32,117 total records listed in the register.
Conclusion
Kazakhstan's NDDA State Register represents a major regional registry of 32,117 total records, with a highly active subset of 14,048 registrations. The register is dominated by medium-risk Class 2a devices (38.2% of active) and features a significant dentistry footprint. The EAEU transition deadline of December 31, 2027 creates a high-stakes window for manufacturers to secure national registrations with unlimited validity. By preparing dual-language Russian/Kazakh labeling and planning for local testing, manufacturers can secure permanent market access in Central Asia's leading economy.
This article is educational and does not constitute legal, regulatory, or clinical advice. Registration requirements change; verify current requirements directly with NDDA before acting.
Sources
- NDDA Official Portal (official): National Center for Expertise of Medicines and Medical Devices,
register.ndda.kz. - Ministry of Health of Kazakhstan Order KR DSM-16 (official): Regulatory framework governing the national registration of medical devices in Kazakhstan.
- Eurasian Economic Commission (EEC) (official): Regulations and decisions governing unified EAEU medical device registration,
eaeunion.org. - Kazakhstan Medical Device Registration (consultancy): Morulaa market access overview,
morulaa.com/regulations/central-asia/central-asia-medical-device-registration-consultant. - EAEU Medical Device Registration and Transition (consultancy): Complife Group regulatory tool,
complifegroup.com/regu-tool/medical-device-registration-in-kazakhstan. - Kazakhstan Updates Registration Framework (consultancy): ARQon Group newsletter on EAEU transition deadlines,
arqon.com/post/kazakhstan-updates-medical-device-registration-framework-as-eaeu-transition-nears. - Register Data (dataset): MedDeviceGuide analysis of the NDDA State Register database extract, snapshot dated June 21, 2026.